N6-ciklopentiladenozin

Izvor: Wikipedia
N6-ciklopentil adenozin
N6-Cyclopentyladenosine.svg
IUPAC ime
Identifikacija
CAS registarski broj 41552-82-3
PubChem[1][2] 657378
Jmol-3D slike Slika 1
Svojstva
Molekulska formula C15H21N5O4
Molarna masa 335.36 g mol−1

 YesY (šta je ovo?)   (verifikuj)

Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala

Infobox references

N6-ciklopentiladenozin (CPA) je lek koji deluje kao selektivni agonist adenozinskog A1 receptora.[3] On uglavnom ima kardiovaskularno dejstva sa samo suptilnim izmenama ponašanja.[4] CPA je u širokoj upotrebi u naučnim istraživanjima adenozinskog receptora i korišten je za razvoj velike familije derivata.[5][6][7][8][9]

Reference[uredi - уреди]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. doi:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Williams M, Braunwalder A, Erickson TJ (February 1986). "Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue". Naunyn-Schmiedeberg's Archives of Pharmacology 332 (2): 179–83. doi:10.1007/BF00511410. PMID 3703020. 
  4. Coffin VL, Spealman RD (April 1987). "Behavioral and cardiovascular effects of analogs of adenosine in cynomolgus monkeys". The Journal of Pharmacology and Experimental Therapeutics 241 (1): 76–83. PMID 3572798. 
  5. Zablocki JA, Wu L, Shryock J, Belardinelli L (2004). "Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)". Current Topics in Medicinal Chemistry 4 (8): 839–54. doi:10.2174/1568026043450998. PMID 15078215. 
  6. Hutchinson SA, Scammells PJ (2004). "A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potential". Current Pharmaceutical Design 10 (17): 2021–39. doi:10.2174/1381612043384204. PMID 15279543. 
  7. Elzein E, Kalla R, Li X, Perry T, Marquart T, Micklatcher M, Li Y, Wu Y, Zeng D, Zablocki J (January 2007). "N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists". Bioorganic & Medicinal Chemistry Letters 17 (1): 161–6. doi:10.1016/j.bmcl.2006.09.065. PMID 17045477. 
  8. Elzein E, Zablocki J (December 2008). "A1 adenosine receptor agonists and their potential therapeutic applications". Expert Opinion on Investigational Drugs 17 (12): 1901–10. doi:10.1517/13543780802497284. PMID 19012505. 
  9. Franchetti P, Cappellacci L, Vita P, Petrelli R, Lavecchia A, Kachler S, Klotz KN, Marabese I, Luongo L, Maione S, Grifantini M (April 2009). "N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice". Journal of Medicinal Chemistry 52 (8): 2393–406. doi:10.1021/jm801456g. PMID 19317449. 

Vidi još[uredi - уреди]

Spoljašnje veze[uredi - уреди]